<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830960</url>
  </required_header>
  <id_info>
    <org_study_id>11299</org_study_id>
    <secondary_id>H7T-MC-TACE</secondary_id>
    <nct_id>NCT00830960</nct_id>
  </id_info>
  <brief_title>A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome</brief_title>
  <official_title>A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the safety and efficacy of prasugrel, administered at different doses
      with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS)
      undergoing percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours Post-Loading Dose (LD) in Primary Cohort (≥60 kg and &lt;75 Years)</measure>
    <time_frame>At 4 hours following LD administration</time_frame>
    <description>ADP-induced PRU represents the rate and extent of ADP-stimulated platelet aggregation and serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of difference in least squares mean (LS mean) PRU values between prasugrel and clopidogrel.
Efficacy analyses are analyzed and presented separately for the LD and maintenance dose (MD) phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Days During Maintenance Dose (MD) Administration in Primary Cohort</measure>
    <time_frame>At 30 days during MD therapy</time_frame>
    <description>Efficacy analyses are analyzed and presented separately for the loading dose (LD) and MD phase. This primary outcome analysis compares PRU for the 3 prasugrel MDs (10 mg, 7.5 mg, and 5 mg) with the clopidogrel 75-mg MD at 30 days post-MD in the primary cohort (participants who weighed ≥60 kg and were &lt;75 years).
ADP-induced PRU serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of LS mean difference between prasugrel and clopidogrel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Minutes, 2 and 4 Hours Post-Loading Dose (LD) in Primary (≥60 kg and &lt;75 Years) and Low Weight/Elderly (&lt;60 kg or ≥75 Years) Cohorts.</measure>
    <time_frame>At 30 minutes, 2 hours, and 4 hours following LD administration</time_frame>
    <description>Efficacy analyses analyzed and presented separately for LD and maintenance dose (MD) phase. Analysis compares PRU for prasugrel LDs (30 mg and 60 mg) with clopidogrel 300-mg LD at 30 minutes post-LD.
Data for Primary Cohort at 4 hours post-LD, already presented in first Primary Outcome Measure, are also presented here.
ADP-induced PRU serves as biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values presented with statistical comparisons of least-squares mean (LS mean) difference between prasugrel and clopidogrel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at During Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort</measure>
    <time_frame>At 30 Days and 90 days during MD therapy</time_frame>
    <description>Efficacy analyses analyzed and presented separately for loading dose (LD) and MD phase. Analysis compares PRU for 3 prasugrel MDs (10 mg, 7.5 mg, and 5 mg) with clopidogrel 75-mg MD at 30 days post-MD.
Data for Primary Cohort at 30 days post-LD, already presented in second Primary Outcome Measure, are also presented here.
ADP-induced PRU serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of least squares (LS) mean difference between prasugrel and clopidogrel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) at 30 Minutes, 2 Hours, and 4 Hours Post-Loading Dose (LD) in Primary in Primary Cohort and Low Weight/Elderly Cohort</measure>
    <time_frame>30 minutes, 2 hours, and 4 hours following LD administration</time_frame>
    <description>A higher percentage (percent inhibition least squares mean [LS mean]) represents greater platelet inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) During the Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort</measure>
    <time_frame>30 days and at 90 days during MD therapy</time_frame>
    <description>A higher percentage (percent inhibition least squares mean [LS mean]) represents greater platelet inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Myocardial Infarction (MI), Stroke, Stent Thrombosis and Urgent Target Vessel Revascularization (UTVR) in Primary Cohort and Low Weight/Elderly Cohort</measure>
    <time_frame>Randomization through end of study (90 days)</time_frame>
    <description>Nonfatal MI: American College of Cardiology (ACC) definition Nonfatal stroke: rapid onset of new, persistent neurologic deficit lasting &gt;24 hours; classified as either ischemic or hemorrhagic based on imaging data, if available, or uncertain cause if imaging data was not available.
Stent thrombosis: defined as definite, probable, or possible, based on Academic Research Consortium definitions.
UTVR: percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) for recurrent ischemia. Revascularization must have included the vessel(s) dilated at the initial procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Non-fatal Stroke</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, or nonfatal stroke.
CV death: death caused by CV event or not clearly attributable to non-CV causes.
Nonfatal MI: per adapted American College of Cardiology definition.
Nonfatal stroke: rapid onset of new, persistent neurologic deficit lasting more than 24 hours; either ischemic or hemorrhagic based on imaging data, if available, or uncertain cause if imaging data was not available.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, or UTVR.
UTVR: percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) for recurrent ischemia. Revascularization must have included the vessel(s) dilated at the initial procedure.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Recurrent Myocardial Ischemia Requiring Hospitalization</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Risk was defined as the number of events of CV death, nonfatal MI, nonfatal stroke or recurrent myocardial ischemia requiring hospitalization.
Recurrent myocardial ischemia requiring hospitalization: rehospitalization for symptoms of myocardial ischemia at rest with either new ST-segment deviation ≥1 mm, or performance of a coronary revascularization procedure percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) during the same hospital stay.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Urgent Target Vessel Revascularization (UTVR), or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, nonfatal stroke, UTVR, or recurrent myocardial ischemia requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Definite or Probable Stent Thrombosis Per ARC (Academic Research Consortium) Definition</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Risk was defined as the number of participants with events of definite or probable stent thrombosis.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Definite, Probable, or Possible Stent Thrombosis Per Academic Research Consortium (ARC) Definition</measure>
    <time_frame>90 days</time_frame>
    <description>Risk was defined as the number of participants with events of definite, probable, or possible stent thrombosis.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of All-cause Death in Primary Cohort and Low Weight/Elderly Cohort</measure>
    <time_frame>Randomization through end of study (90 days)</time_frame>
    <description>Risk was defined as the number of participants with events of all-cause death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non-coronary Artery Bypass Graft (CABG) Related Thrombolysis in Myocardial Infarction (TIMI) Life-threatening (a Subset of Non-CABG-related TIMI Major Bleeding), Major, Minor, and Minimal Bleeding</measure>
    <time_frame>Randomization through end of study (90 days)</time_frame>
    <description>Bleeding events were classified and analyzed in accordance with the TIMI criteria definitions.
Major bleeding: any intracranial hemorrhage (ICR) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL) from baseline.
Minor bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 but &lt;5 gm/dL from baseline.
Insignificant bleeding: any bleeding event that does not meet criteria for a Major or Minor bleed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CABG-related TIMI Major or Minor Bleeding.</measure>
    <time_frame>Randomization through end of study (90 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Healthcare Resource Utilization</measure>
    <time_frame>Initial hospitalization, 30 days, 90 days</time_frame>
    <description>Healthcare resource utilization data were modeled from historical analyses to determine initial hospitalization costs, total 30-day medical care costs, and total 90-day medical care costs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Variation Related to Drug Metabolism and Transport Substudy Result Summary</measure>
    <time_frame>Baseline to 4 hours post-loading dose (LD), 30 days and 90 days during maintenance dose (MD) phase</time_frame>
    <description>The primary hypothesis for the genetics substudy was that CYP2C19 genetic variation has a significant effect on pharmacodynamic (PD) response to clopidogrel but not on PD response to prasugrel per change in PRU as measured by the Accumetrics VerifyNow P2Y12 device.
Participants were classified by CYP2C19 genotype into predicted metabolic phenotypes according to literature-based functional predictions. These classifications were clustered into 2 groups: extensive metabolizer (EM) and reduced metabolizer (RM).
A higher value for change in PRU indicates a greater level of platelet inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of CV Death, Nonfatal MI, Nonfatal Stroke, UTVR, or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Urgent Target Vessel Revascularization (UTVR), or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel 60/10 Primary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose 60 mg followed by maintenance dose 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel 30/7.5 Primary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose 30 mg followed by maintenance dose 7.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel 30/5 Primary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose 30 mg followed by maintenance dose 5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 300/75 Primary</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading dose 300 mg followed by maintenance dose 75 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel 30/5 Low Weight/Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose 30 mg followed by maintenance dose 5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 300/75 Low Weight/Elderly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading dose 300 mg followed by maintenance dose 75 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Oral, daily, 90 days</description>
    <arm_group_label>Prasugrel 60/10 Primary</arm_group_label>
    <arm_group_label>Prasugrel 30/7.5 Primary</arm_group_label>
    <arm_group_label>Prasugrel 30/5 Primary</arm_group_label>
    <arm_group_label>Prasugrel 30/5 Low Weight/Elderly</arm_group_label>
    <other_name>LY640315</other_name>
    <other_name>Effient</other_name>
    <other_name>Efient</other_name>
    <other_name>CS-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Oral, daily, 90 days</description>
    <arm_group_label>Clopidogrel 300/75 Primary</arm_group_label>
    <arm_group_label>Clopidogrel 300/75 Low Weight/Elderly</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A person who has been diagnosed with acute coronary syndrome (ACS) and is to undergo a
             percutaneous coronary intervention (PCI)

          -  A person who is of East or Southeast Asian descent

          -  A person who is of the legal age of 18 (or age 21 in Singapore) and is mentally
             competent to provide a signed written informed consent before entering the study

          -  If a woman is of childbearing potential, she must test negative for pregnancy and
             agree to use a reliable method of birth control

        Exclusion Criteria:

          -  A person who has a severe cardiovascular condition such as cardiogenic shock at the
             time of randomization, ventricular arrhythmias or congestive heart failure

          -  A person who is at an increased risk of bleeding (e.g. active internal bleeding,
             history of bleeding disorder, recent fibrinolytic therapy before randomization into
             the study)

          -  A person who has prior history of any one of the following: ischemic or hemorrhagic
             stroke; intracranial neoplasm, arteriovenous malformation, or aneurysm; prior history
             of transient ischemic attack (TIA)

          -  A person who needs to take other antiplatelet therapy other than Aspirin for the
             duration of the study

          -  A person who receives daily treatment with nonsteroidal anti-inflammatory drugs
             (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued

          -  A person who has a severe liver disease, such as cirrhosis

          -  A person who has a condition such as alcoholism, mental illness, or drug dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wenzhou</city>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Xi'An</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kwang Ju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seongnam-Si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>135 720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suwon-City</city>
        <zip>442-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <results_first_submitted>June 17, 2011</results_first_submitted>
  <results_first_submitted_qc>September 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2011</results_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study had 4 treatment arms and had 2 cohorts; a Primary Cohort (≥60 kilograms [kg] and age &lt;75 years) and a Low Weight/Elderly cohort (&lt;60 kg or age ≥75 years). Randomization was stratified by country, cohort and anticipated glycoprotein (GP) IIb/IIIa inhibitor use.</recruitment_details>
      <pre_assignment_details>One participant who was enrolled based on weight &gt;60 kg was not assigned to primary cohort due to no weight entered in case report form.
Low Weight/Elderly Cohort was only assigned to prasugrel 30-mg loading dose (LD)/5-mg maintenance dose (MD) or clopidogrel 300-mg LD/75-mg MD due to evidence of increased bleeding risk for these populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel 60/10 Primary</title>
          <description>Population includes participants randomly assigned to receive prasugrel 60-mg loading dose (LD) followed by prasugrel 10-mg maintenance dose (MD) daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
        </group>
        <group group_id="P2">
          <title>Prasugrel 30/7.5 Primary</title>
          <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
        </group>
        <group group_id="P3">
          <title>Prasugrel 30/5 Primary</title>
          <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
        </group>
        <group group_id="P4">
          <title>Clopidogrel 300/75 Primary</title>
          <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
        </group>
        <group group_id="P5">
          <title>Prasugrel 30/5 Low Weight/Elderly</title>
          <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
        </group>
        <group group_id="P6">
          <title>Clopidogrel 300/75 Low Weight/Elderly</title>
          <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124">Number of participants &quot;STARTED&quot; equals the number of participants randomized.</participants>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="138"/>
                <participants group_id="P5" count="96"/>
                <participants group_id="P6" count="100">Total 720 participants were randomized; 1 was not included in a cohort as baseline weight missing.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="117">Baseline Characteristics (below) include those who received ≥1 dose study drug, not all who STARTED.</participants>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="133"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="91"/>
                <participants group_id="P6" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="64">6 participants not completed due to death; 1 additional death occurred after study discontinuation.</participants>
                <participants group_id="P6" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No study drug received</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel 60/10 Primary</title>
          <description>Study treatment of prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)
Reporting groups for Baseline Characteristics do not include all randomized participants (n=720), but includes all randomized participants who received at least 1 dose of study drug.</description>
        </group>
        <group group_id="B2">
          <title>Prasugrel 30/7.5 Primary</title>
          <description>Study treatment of prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
        </group>
        <group group_id="B3">
          <title>Prasugrel 30/5 Primary</title>
          <description>Study treatment of prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
        </group>
        <group group_id="B4">
          <title>Clopidogrel 300/75 Primary</title>
          <description>Study treatment of clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
        </group>
        <group group_id="B5">
          <title>Prasugrel 30/5 Low Weight/Elderly</title>
          <description>Study treatment of prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
        </group>
        <group group_id="B6">
          <title>Clopidogrel 300/75 Low Weight/Elderly</title>
          <description>Study treatment of clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="133"/>
            <count group_id="B4" value="135"/>
            <count group_id="B5" value="91"/>
            <count group_id="B6" value="93"/>
            <count group_id="B7" value="691"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Total mean age is based on all randomized participants who received at least 1 dose of study drug, and for whom information was available (n=689).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mean Age Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="9.83"/>
                    <measurement group_id="B2" value="57.7" spread="9.47"/>
                    <measurement group_id="B3" value="57.2" spread="10.49"/>
                    <measurement group_id="B4" value="58.3" spread="8.95"/>
                    <measurement group_id="B5" value="68.5" spread="9.74"/>
                    <measurement group_id="B6" value="69.1" spread="12.08"/>
                    <measurement group_id="B7" value="60.8" spread="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="61"/>
                    <measurement group_id="B7" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms per square meter (kg/m²)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>BMI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.86" spread="2.907"/>
                    <measurement group_id="B2" value="25.75" spread="2.990"/>
                    <measurement group_id="B3" value="26.06" spread="2.637"/>
                    <measurement group_id="B4" value="26.19" spread="2.999"/>
                    <measurement group_id="B5" value="22.02" spread="4.106"/>
                    <measurement group_id="B6" value="22.10" spread="3.166"/>
                    <measurement group_id="B7" value="24.74" spread="3.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qualifying Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Unstable angina (UA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ST segment elevation myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST segment elevation myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours Post-Loading Dose (LD) in Primary Cohort (≥60 kg and &lt;75 Years)</title>
        <description>ADP-induced PRU represents the rate and extent of ADP-stimulated platelet aggregation and serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of difference in least squares mean (LS mean) PRU values between prasugrel and clopidogrel.
Efficacy analyses are analyzed and presented separately for the LD and maintenance dose (MD) phase.</description>
        <time_frame>At 4 hours following LD administration</time_frame>
        <population>Per Protocol Set (PPS) LD population
PPS: all randomized participants with ≥1 dose study drug, ≥1 post-baseline platelet aggregation measurement, no significant protocol violations
LD population: never used glycoprotein (GP) IIb/IIIa inhibitor during index hospitalization and received percutaneous coronary intervention (PCI) for index event</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60-mg LD Primary</title>
            <description>Population includes participants in primary cohort randomly assigned to receive prasugrel 60-mg LD</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30-mg LD Primary</title>
            <description>Population includes participants in primary cohort who were randomly assigned to receive a prasugrel 30-mg LD (including participants in both Prasugrel 30/7.5 Primary and Prasugrel 30/5 Primary populations).</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 300-mg LD Primary</title>
            <description>Population includes participants in primary cohort who were randomly assigned to receive a clopidogrel 300-mg LD.</description>
          </group>
        </group_list>
        <measure>
          <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours Post-Loading Dose (LD) in Primary Cohort (≥60 kg and &lt;75 Years)</title>
          <description>ADP-induced PRU represents the rate and extent of ADP-stimulated platelet aggregation and serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of difference in least squares mean (LS mean) PRU values between prasugrel and clopidogrel.
Efficacy analyses are analyzed and presented separately for the LD and maintenance dose (MD) phase.</description>
          <population>Per Protocol Set (PPS) LD population
PPS: all randomized participants with ≥1 dose study drug, ≥1 post-baseline platelet aggregation measurement, no significant protocol violations
LD population: never used glycoprotein (GP) IIb/IIIa inhibitor during index hospitalization and received percutaneous coronary intervention (PCI) for index event</population>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" spread="104.86"/>
                    <measurement group_id="O2" value="124.2" spread="117.28"/>
                    <measurement group_id="O3" value="261.8" spread="83.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect was used.
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate denominator degrees of freedom for fixed effects. Invalid measurements excluded.</method_desc>
            <param_type>Least Square (LS) Mean Difference in PRU</param_type>
            <param_value>-183</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-229</ci_lower_limit>
            <ci_upper_limit>-137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect was used.
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate denominator degrees of freedom for fixed effects. Invalid measurements excluded.</method_desc>
            <param_type>LS Mean Difference in PRU</param_type>
            <param_value>-139</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-177</ci_lower_limit>
            <ci_upper_limit>-102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Minutes, 2 and 4 Hours Post-Loading Dose (LD) in Primary (≥60 kg and &lt;75 Years) and Low Weight/Elderly (&lt;60 kg or ≥75 Years) Cohorts.</title>
        <description>Efficacy analyses analyzed and presented separately for LD and maintenance dose (MD) phase. Analysis compares PRU for prasugrel LDs (30 mg and 60 mg) with clopidogrel 300-mg LD at 30 minutes post-LD.
Data for Primary Cohort at 4 hours post-LD, already presented in first Primary Outcome Measure, are also presented here.
ADP-induced PRU serves as biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values presented with statistical comparisons of least-squares mean (LS mean) difference between prasugrel and clopidogrel.</description>
        <time_frame>At 30 minutes, 2 hours, and 4 hours following LD administration</time_frame>
        <population>Per Protocol Set (PPS) LD population PPS: all randomized participants with at least 1 dose study drug, ≥1 post-baseline platelet aggregation measurement, no significant protocol violations
LD population: never used glycoprotein (GP)IIb/IIIa inhibitor during index hospitalization, received percutaneous coronary intervention (PCI) for index event</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60-mg LD Primary</title>
            <description>Population includes participants in primary cohort randomly assigned to receive prasugrel 60-mg LD</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30-mg LD Primary</title>
            <description>Population includes participants in primary cohort who were randomly assigned to receive a prasugrel 30-mg LD (including participants in both Prasugrel 30/7.5 Primary and Prasugrel 30/5 Primary populations).</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 300-mg LD Primary</title>
            <description>Population includes participants in primary cohort who were randomly assigned to receive a clopidogrel 300-mg LD.</description>
          </group>
          <group group_id="O4">
            <title>Prasugrel 30-mg LD Low Weight/Elderly</title>
            <description>Population includes participants in low weight/elderly cohort who were randomly assigned to receive a prasugrel 30-mg LD.</description>
          </group>
          <group group_id="O5">
            <title>Clopidogrel 300-mg LD Low Weight/Elderly</title>
            <description>Population includes participants in low weight/elderly cohort who randomly assigned to receive a clopidogrel 300-mg LD.</description>
          </group>
        </group_list>
        <measure>
          <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Minutes, 2 and 4 Hours Post-Loading Dose (LD) in Primary (≥60 kg and &lt;75 Years) and Low Weight/Elderly (&lt;60 kg or ≥75 Years) Cohorts.</title>
          <description>Efficacy analyses analyzed and presented separately for LD and maintenance dose (MD) phase. Analysis compares PRU for prasugrel LDs (30 mg and 60 mg) with clopidogrel 300-mg LD at 30 minutes post-LD.
Data for Primary Cohort at 4 hours post-LD, already presented in first Primary Outcome Measure, are also presented here.
ADP-induced PRU serves as biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values presented with statistical comparisons of least-squares mean (LS mean) difference between prasugrel and clopidogrel.</description>
          <population>Per Protocol Set (PPS) LD population PPS: all randomized participants with at least 1 dose study drug, ≥1 post-baseline platelet aggregation measurement, no significant protocol violations
LD population: never used glycoprotein (GP)IIb/IIIa inhibitor during index hospitalization, received percutaneous coronary intervention (PCI) for index event</population>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 min (n=40, n=79, n=48, n=33, n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.5" spread="109.02"/>
                    <measurement group_id="O2" value="280.4" spread="112.58"/>
                    <measurement group_id="O3" value="312.1" spread="72.41"/>
                    <measurement group_id="O4" value="311.2" spread="96.46"/>
                    <measurement group_id="O5" value="379.5" spread="53.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours (n=37, n=80, n=49, n=33, n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.9" spread="116.48"/>
                    <measurement group_id="O2" value="178.8" spread="128.37"/>
                    <measurement group_id="O3" value="289.5" spread="71.77"/>
                    <measurement group_id="O4" value="171.8" spread="123.37"/>
                    <measurement group_id="O5" value="339.0" spread="74.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours (n=35, n=79, n=44, n=33, n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" spread="104.86"/>
                    <measurement group_id="O2" value="124.2" spread="117.28"/>
                    <measurement group_id="O3" value="261.8" spread="83.87"/>
                    <measurement group_id="O4" value="127.3" spread="106.38"/>
                    <measurement group_id="O5" value="337.8" spread="85.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <p_value_desc>P-value for 30 minutes post-LD
Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-97</ci_lower_limit>
            <ci_upper_limit>-17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0365</p_value>
            <p_value_desc>P-value for 30 minutes post-LD
Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU = prasugrel - clopidogrel</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68</ci_lower_limit>
            <ci_upper_limit>-2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-value for 30 minutes post-LD Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-104</ci_lower_limit>
            <ci_upper_limit>-32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 2 hours post-LD
Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-160</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-211</ci_lower_limit>
            <ci_upper_limit>-110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 2 hours post-LD
Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-115</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-156</ci_lower_limit>
            <ci_upper_limit>-73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 2 hours post-LD
Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-171</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-216</ci_lower_limit>
            <ci_upper_limit>-125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 hours post-LD
Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-212</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-259</ci_lower_limit>
            <ci_upper_limit>-167</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at During Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort</title>
        <description>Efficacy analyses analyzed and presented separately for loading dose (LD) and MD phase. Analysis compares PRU for 3 prasugrel MDs (10 mg, 7.5 mg, and 5 mg) with clopidogrel 75-mg MD at 30 days post-MD.
Data for Primary Cohort at 30 days post-LD, already presented in second Primary Outcome Measure, are also presented here.
ADP-induced PRU serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of least squares (LS) mean difference between prasugrel and clopidogrel.</description>
        <time_frame>At 30 Days and 90 days during MD therapy</time_frame>
        <population>Per Protocol Set (PPS) MD population PPS: all randomized participants who had at least 1 dose of study drug, ≥1 post-baseline platelet aggregation measurement, and no significant protocol violations in MD population: received percutaneous coronary intervention (PCI) for index event</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg loading dose (LD) followed by prasugrel 10-mg maintenance dose (MD) daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at During Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort</title>
          <description>Efficacy analyses analyzed and presented separately for loading dose (LD) and MD phase. Analysis compares PRU for 3 prasugrel MDs (10 mg, 7.5 mg, and 5 mg) with clopidogrel 75-mg MD at 30 days post-MD.
Data for Primary Cohort at 30 days post-LD, already presented in second Primary Outcome Measure, are also presented here.
ADP-induced PRU serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of least squares (LS) mean difference between prasugrel and clopidogrel.</description>
          <population>Per Protocol Set (PPS) MD population PPS: all randomized participants who had at least 1 dose of study drug, ≥1 post-baseline platelet aggregation measurement, and no significant protocol violations in MD population: received percutaneous coronary intervention (PCI) for index event</population>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days (n=69, n=63, n=69, n=78, n=47, n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="65.56"/>
                    <measurement group_id="O2" value="99.3" spread="72.63"/>
                    <measurement group_id="O3" value="150.8" spread="77.76"/>
                    <measurement group_id="O4" value="206.5" spread="72.68"/>
                    <measurement group_id="O5" value="134.2" spread="80.29"/>
                    <measurement group_id="O6" value="237.5" spread="108.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Days (n=60, n=57, n=64, n=72, n=43, n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" spread="55.99"/>
                    <measurement group_id="O2" value="89.4" spread="91.75"/>
                    <measurement group_id="O3" value="138.5" spread="80.42"/>
                    <measurement group_id="O4" value="188.3" spread="81.24"/>
                    <measurement group_id="O5" value="128.5" spread="70.42"/>
                    <measurement group_id="O6" value="219.6" spread="95.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 30 days. A linear mixed effects model including treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU was prasugrel - clopidogrel.</p_value_desc>
            <method>LS Mean Difference in PRU</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in PRU</param_type>
            <param_value>-119</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-166</ci_lower_limit>
            <ci_upper_limit>-73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 90 days. A linear mixed effects model including treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU was prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in PRU</param_type>
            <param_value>-113</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-154</ci_lower_limit>
            <ci_upper_limit>-73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 90 days. A linear mixed effects model including treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU was prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in PRU</param_type>
            <param_value>-85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-121</ci_lower_limit>
            <ci_upper_limit>-48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0647</p_value>
            <p_value_desc>P-value for 90 days. A linear mixed effects model including treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU was prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in PRU</param_type>
            <param_value>-35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 90 days. A linear mixed effects model including treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect
Difference in PRU was prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in PRU</param_type>
            <param_value>-100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-143</ci_lower_limit>
            <ci_upper_limit>-57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) at 30 Minutes, 2 Hours, and 4 Hours Post-Loading Dose (LD) in Primary in Primary Cohort and Low Weight/Elderly Cohort</title>
        <description>A higher percentage (percent inhibition least squares mean [LS mean]) represents greater platelet inhibition.</description>
        <time_frame>30 minutes, 2 hours, and 4 hours following LD administration</time_frame>
        <population>Per Protocol Set (PPS) LD population PPS: all randomized participants with at least 1 dose study drug, ≥1 post-baseline platelet aggregation measurement, no significant protocol violations LD population: never used glycoprotein (GP) IIb/IIIa inhibitor during index hospitalization, received percutaneous coronary intervention (PCI) for index event</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60-mg LD Primary</title>
            <description>Population includes participants in primary cohort who were treated with a prasugrel 60-mg LD.</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30-mg LD Primary</title>
            <description>Population includes participants in primary cohort who were treated with a prasugrel 30-mg LD(including participants in both Prasugrel 30/7.5 Primary and Prasugrel 30/5 Primary populations).</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 300-mg LD Primary</title>
            <description>Population includes participants in primary cohort who were treated with a clopidogrel 300-mg LD.</description>
          </group>
          <group group_id="O4">
            <title>Prasugrel 30-mg LD Low Weight/Elderly</title>
            <description>Population includes participants in low weight/elderly cohort who were treated with a prasugrel 30-mg LD.</description>
          </group>
          <group group_id="O5">
            <title>Clopidogrel 300-mg LD Low Weight/Elderly</title>
            <description>Population includes participants in low weight/elderly cohort who were treated with a clopidogrel 300-mg LD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) at 30 Minutes, 2 Hours, and 4 Hours Post-Loading Dose (LD) in Primary in Primary Cohort and Low Weight/Elderly Cohort</title>
          <description>A higher percentage (percent inhibition least squares mean [LS mean]) represents greater platelet inhibition.</description>
          <population>Per Protocol Set (PPS) LD population PPS: all randomized participants with at least 1 dose study drug, ≥1 post-baseline platelet aggregation measurement, no significant protocol violations LD population: never used glycoprotein (GP) IIb/IIIa inhibitor during index hospitalization, received percutaneous coronary intervention (PCI) for index event</population>
          <units>Percent inhibition</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes (n=40, n=79, n=47, n=32, n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="-5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours (n=37, n=80, n=48, n=33, n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="-2"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours (n=34, n=79, n=43, n=33, n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <p_value_desc>P-value for 30 minutes post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0647</p_value>
            <p_value_desc>P-value for 30 minutes post-LD Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0054</p_value>
            <p_value_desc>P-value for 30 minutes post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 2 hours post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36</ci_lower_limit>
            <ci_upper_limit>66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 2 hours post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23</ci_lower_limit>
            <ci_upper_limit>48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 2 hours post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36</ci_lower_limit>
            <ci_upper_limit>61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 hours post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47</ci_lower_limit>
            <ci_upper_limit>76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 hours post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36</ci_lower_limit>
            <ci_upper_limit>59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 hours post-LD
Linear mixed effects model: treatment, visit (0.5 hours to 4 hours), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44</ci_lower_limit>
            <ci_upper_limit>68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) During the Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort</title>
        <description>A higher percentage (percent inhibition least squares mean [LS mean]) represents greater platelet inhibition.</description>
        <time_frame>30 days and at 90 days during MD therapy</time_frame>
        <population>Per Protocol Set (PPS) MD population
PPS: all randomized participants who had at least 1 dose of study drug, ≥1 post-baseline platelet aggregation measurement, and no significant protocol violations
MD population: received percutaneous coronary intervention (PCI) for index event</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) During the Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort</title>
          <description>A higher percentage (percent inhibition least squares mean [LS mean]) represents greater platelet inhibition.</description>
          <population>Per Protocol Set (PPS) MD population
PPS: all randomized participants who had at least 1 dose of study drug, ≥1 post-baseline platelet aggregation measurement, and no significant protocol violations
MD population: received percutaneous coronary intervention (PCI) for index event</population>
          <units>Percent inhibition</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Days (n=69, n=63, n=68, n=78, n=47, n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="68"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Days (n=60, n=57, n=64, n=72, n=43, n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="69"/>
                    <measurement group_id="O6" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 30 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27</ci_lower_limit>
            <ci_upper_limit>50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 30 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21</ci_lower_limit>
            <ci_upper_limit>42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <p_value_desc>P-value for 30 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6</ci_lower_limit>
            <ci_upper_limit>28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 30 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24</ci_lower_limit>
            <ci_upper_limit>50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value for 90 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18</ci_lower_limit>
            <ci_upper_limit>52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P-value for 90 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13</ci_lower_limit>
            <ci_upper_limit>44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1898</p_value>
            <p_value_desc>P-value for 90 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 90 days post-LD
Linear mixed effects model: treatment, visit (30, 90 days during MD), treatment-by-visit interaction, gender, country as fixed effects, participant as random effect
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS Mean Difference in Percent Inhibition</param_type>
            <param_value>32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18</ci_lower_limit>
            <ci_upper_limit>45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Myocardial Infarction (MI), Stroke, Stent Thrombosis and Urgent Target Vessel Revascularization (UTVR) in Primary Cohort and Low Weight/Elderly Cohort</title>
        <description>Nonfatal MI: American College of Cardiology (ACC) definition Nonfatal stroke: rapid onset of new, persistent neurologic deficit lasting &gt;24 hours; classified as either ischemic or hemorrhagic based on imaging data, if available, or uncertain cause if imaging data was not available.
Stent thrombosis: defined as definite, probable, or possible, based on Academic Research Consortium definitions.
UTVR: percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) for recurrent ischemia. Revascularization must have included the vessel(s) dilated at the initial procedure</description>
        <time_frame>Randomization through end of study (90 days)</time_frame>
        <population>Full analysis set (FAS)
FAS: all randomized subjects who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg loading dose (LD) followed by prasugrel 10-mg maintenance dose (MD) daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Myocardial Infarction (MI), Stroke, Stent Thrombosis and Urgent Target Vessel Revascularization (UTVR) in Primary Cohort and Low Weight/Elderly Cohort</title>
          <description>Nonfatal MI: American College of Cardiology (ACC) definition Nonfatal stroke: rapid onset of new, persistent neurologic deficit lasting &gt;24 hours; classified as either ischemic or hemorrhagic based on imaging data, if available, or uncertain cause if imaging data was not available.
Stent thrombosis: defined as definite, probable, or possible, based on Academic Research Consortium definitions.
UTVR: percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) for recurrent ischemia. Revascularization must have included the vessel(s) dilated at the initial procedure</description>
          <population>Full analysis set (FAS)
FAS: all randomized subjects who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonfatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonfatal Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UTVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Days During Maintenance Dose (MD) Administration in Primary Cohort</title>
        <description>Efficacy analyses are analyzed and presented separately for the loading dose (LD) and MD phase. This primary outcome analysis compares PRU for the 3 prasugrel MDs (10 mg, 7.5 mg, and 5 mg) with the clopidogrel 75-mg MD at 30 days post-MD in the primary cohort (participants who weighed ≥60 kg and were &lt;75 years).
ADP-induced PRU serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of LS mean difference between prasugrel and clopidogrel.</description>
        <time_frame>At 30 days during MD therapy</time_frame>
        <population>Per protocol set (PPS) MD population
PPS: all randomized participants who had at least 1 dose of study drug, ≥1 post-baseline platelet aggregation measurement, and no significant protocol violations
MD population: received percutaneous coronary intervention (PCI) for index event</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants in primary cohort randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants in primary cohort randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants in primary cohort randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants in primary cohort randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Days During Maintenance Dose (MD) Administration in Primary Cohort</title>
          <description>Efficacy analyses are analyzed and presented separately for the loading dose (LD) and MD phase. This primary outcome analysis compares PRU for the 3 prasugrel MDs (10 mg, 7.5 mg, and 5 mg) with the clopidogrel 75-mg MD at 30 days post-MD in the primary cohort (participants who weighed ≥60 kg and were &lt;75 years).
ADP-induced PRU serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition.
Observed PRU values are presented with statistical comparisons of LS mean difference between prasugrel and clopidogrel.</description>
          <population>Per protocol set (PPS) MD population
PPS: all randomized participants who had at least 1 dose of study drug, ≥1 post-baseline platelet aggregation measurement, and no significant protocol violations
MD population: received percutaneous coronary intervention (PCI) for index event</population>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="65.56"/>
                    <measurement group_id="O2" value="99.3" spread="72.63"/>
                    <measurement group_id="O3" value="150.8" spread="77.76"/>
                    <measurement group_id="O4" value="206.5" spread="72.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect was used.
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-110</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-143</ci_lower_limit>
            <ci_upper_limit>-76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect was used.
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-123</ci_lower_limit>
            <ci_upper_limit>-60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect was used.
Difference in PRU = prasugrel - clopidogrel.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger method was used to estimate the denominator degrees of freedom for fixed effects. Invalid measurements were excluded.</method_desc>
            <param_type>LS mean difference in PRU</param_type>
            <param_value>-51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83</ci_lower_limit>
            <ci_upper_limit>-19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Non-fatal Stroke</title>
        <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, or nonfatal stroke.
CV death: death caused by CV event or not clearly attributable to non-CV causes.
Nonfatal MI: per adapted American College of Cardiology definition.
Nonfatal stroke: rapid onset of new, persistent neurologic deficit lasting more than 24 hours; either ischemic or hemorrhagic based on imaging data, if available, or uncertain cause if imaging data was not available.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
        <time_frame>30 days and 90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg loading dose (LD) followed by prasugrel 10-mg maintenance dose (MD) daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by prasugrel 75-mg MD daily in the Low Weight/Elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Non-fatal Stroke</title>
          <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, or nonfatal stroke.
CV death: death caused by CV event or not clearly attributable to non-CV causes.
Nonfatal MI: per adapted American College of Cardiology definition.
Nonfatal stroke: rapid onset of new, persistent neurologic deficit lasting more than 24 hours; either ischemic or hemorrhagic based on imaging data, if available, or uncertain cause if imaging data was not available.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
          <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)</title>
        <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, or UTVR.
UTVR: percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) for recurrent ischemia. Revascularization must have included the vessel(s) dilated at the initial procedure.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
        <time_frame>30 days and 90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)</title>
          <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, or UTVR.
UTVR: percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) for recurrent ischemia. Revascularization must have included the vessel(s) dilated at the initial procedure.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
          <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Recurrent Myocardial Ischemia Requiring Hospitalization</title>
        <description>Risk was defined as the number of events of CV death, nonfatal MI, nonfatal stroke or recurrent myocardial ischemia requiring hospitalization.
Recurrent myocardial ischemia requiring hospitalization: rehospitalization for symptoms of myocardial ischemia at rest with either new ST-segment deviation ≥1 mm, or performance of a coronary revascularization procedure percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) during the same hospital stay.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
        <time_frame>30 days and 90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Recurrent Myocardial Ischemia Requiring Hospitalization</title>
          <description>Risk was defined as the number of events of CV death, nonfatal MI, nonfatal stroke or recurrent myocardial ischemia requiring hospitalization.
Recurrent myocardial ischemia requiring hospitalization: rehospitalization for symptoms of myocardial ischemia at rest with either new ST-segment deviation ≥1 mm, or performance of a coronary revascularization procedure percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) during the same hospital stay.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
          <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Urgent Target Vessel Revascularization (UTVR), or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</title>
        <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, nonfatal stroke, UTVR, or recurrent myocardial ischemia requiring hospitalization.</description>
        <time_frame>30 days and 90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Urgent Target Vessel Revascularization (UTVR), or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</title>
          <description>Risk was defined as the number of participants with events of CV death, nonfatal MI, nonfatal stroke, UTVR, or recurrent myocardial ischemia requiring hospitalization.</description>
          <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Definite or Probable Stent Thrombosis Per ARC (Academic Research Consortium) Definition</title>
        <description>Risk was defined as the number of participants with events of definite or probable stent thrombosis.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
        <time_frame>30 days and 90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Definite or Probable Stent Thrombosis Per ARC (Academic Research Consortium) Definition</title>
          <description>Risk was defined as the number of participants with events of definite or probable stent thrombosis.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
          <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Definite, Probable, or Possible Stent Thrombosis Per Academic Research Consortium (ARC) Definition</title>
        <description>Risk was defined as the number of participants with events of definite, probable, or possible stent thrombosis.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
        <time_frame>90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Definite, Probable, or Possible Stent Thrombosis Per Academic Research Consortium (ARC) Definition</title>
          <description>Risk was defined as the number of participants with events of definite, probable, or possible stent thrombosis.
As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed.</description>
          <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of All-cause Death in Primary Cohort and Low Weight/Elderly Cohort</title>
        <description>Risk was defined as the number of participants with events of all-cause death.</description>
        <time_frame>Randomization through end of study (90 days)</time_frame>
        <population>Full Analysis Set (FAS): all randomized subjects who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of All-cause Death in Primary Cohort and Low Weight/Elderly Cohort</title>
          <description>Risk was defined as the number of participants with events of all-cause death.</description>
          <population>Full Analysis Set (FAS): all randomized subjects who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.255</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.427</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.683</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Non-coronary Artery Bypass Graft (CABG) Related Thrombolysis in Myocardial Infarction (TIMI) Life-threatening (a Subset of Non-CABG-related TIMI Major Bleeding), Major, Minor, and Minimal Bleeding</title>
        <description>Bleeding events were classified and analyzed in accordance with the TIMI criteria definitions.
Major bleeding: any intracranial hemorrhage (ICR) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL) from baseline.
Minor bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 but &lt;5 gm/dL from baseline.
Insignificant bleeding: any bleeding event that does not meet criteria for a Major or Minor bleed.</description>
        <time_frame>Randomization through end of study (90 days)</time_frame>
        <population>Safety analysis set (SAS): all randomized participants with at least 1 dose of study drug
Two (2) participants had no event date; time from start of therapy to event was missing and thus they were not included in this table.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Non-coronary Artery Bypass Graft (CABG) Related Thrombolysis in Myocardial Infarction (TIMI) Life-threatening (a Subset of Non-CABG-related TIMI Major Bleeding), Major, Minor, and Minimal Bleeding</title>
          <description>Bleeding events were classified and analyzed in accordance with the TIMI criteria definitions.
Major bleeding: any intracranial hemorrhage (ICR) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL) from baseline.
Minor bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 but &lt;5 gm/dL from baseline.
Insignificant bleeding: any bleeding event that does not meet criteria for a Major or Minor bleed.</description>
          <population>Safety analysis set (SAS): all randomized participants with at least 1 dose of study drug
Two (2) participants had no event date; time from start of therapy to event was missing and thus they were not included in this table.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤3 Days of LD Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤3 Days of LD Life Threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤3 Days of LD Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤3 Days of LD Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 Days of LD Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 Days of LD Life Threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 Days of LD Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 Days of LD Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of CABG-related TIMI Major or Minor Bleeding.</title>
        <time_frame>Randomization through end of study (90 days)</time_frame>
        <population>Safety Analysis Set (SAS): all randomized participants with at least 1 dose of study drug
In 10 participants, study drug discontinued due to planned CABG. 1 participant had CABG reported on revascularization case report form (CRF); no reports of CABG bleeding event</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of CABG-related TIMI Major or Minor Bleeding.</title>
          <population>Safety Analysis Set (SAS): all randomized participants with at least 1 dose of study drug
In 10 participants, study drug discontinued due to planned CABG. 1 participant had CABG reported on revascularization case report form (CRF); no reports of CABG bleeding event</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inpatient Healthcare Resource Utilization</title>
        <description>Healthcare resource utilization data were modeled from historical analyses to determine initial hospitalization costs, total 30-day medical care costs, and total 90-day medical care costs.</description>
        <time_frame>Initial hospitalization, 30 days, 90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, inpatient healthcare resource utilization data were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Inpatient Healthcare Resource Utilization</title>
          <description>Healthcare resource utilization data were modeled from historical analyses to determine initial hospitalization costs, total 30-day medical care costs, and total 90-day medical care costs.</description>
          <population>As a consequence of the overall low number of reported clinical events, inpatient healthcare resource utilization data were not analyzed; thus zero participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Variation Related to Drug Metabolism and Transport Substudy Result Summary</title>
        <description>The primary hypothesis for the genetics substudy was that CYP2C19 genetic variation has a significant effect on pharmacodynamic (PD) response to clopidogrel but not on PD response to prasugrel per change in PRU as measured by the Accumetrics VerifyNow P2Y12 device.
Participants were classified by CYP2C19 genotype into predicted metabolic phenotypes according to literature-based functional predictions. These classifications were clustered into 2 groups: extensive metabolizer (EM) and reduced metabolizer (RM).
A higher value for change in PRU indicates a greater level of platelet inhibition.</description>
        <time_frame>Baseline to 4 hours post-loading dose (LD), 30 days and 90 days during maintenance dose (MD) phase</time_frame>
        <population>Pharmacodynamic analysis set is subset of FAS (≥1 genetics sample, ≥1 dose of study drug, ≥1 post-baseline PRU measurement, no significant protocol violations). Genetics subset LD population never used glycoprotein (GP) IIb/IIIa inhibitor during index hospitalization.
Participants classified as EM or RM. Invalid measurements of PRU were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 PD</title>
            <description>Population includes participants in genetics substudy who were randomly assigned to receive a prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Primary Cohort.</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 PD</title>
            <description>Population includes participants in genetics substudy who were randomly assigned to receive a prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the Primary and Low Weight/Elderly Cohorts combined.</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 PD</title>
            <description>Population includes participants in genetics substudy who were randomly assigned to receive a prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the Primary and Low Weight/Elderly Cohorts combined.</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 PD</title>
            <description>Population includes participants in genetics substudy who were randomly assigned to receive a clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the Primary and Low Weight/Elderly Cohorts combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Variation Related to Drug Metabolism and Transport Substudy Result Summary</title>
          <description>The primary hypothesis for the genetics substudy was that CYP2C19 genetic variation has a significant effect on pharmacodynamic (PD) response to clopidogrel but not on PD response to prasugrel per change in PRU as measured by the Accumetrics VerifyNow P2Y12 device.
Participants were classified by CYP2C19 genotype into predicted metabolic phenotypes according to literature-based functional predictions. These classifications were clustered into 2 groups: extensive metabolizer (EM) and reduced metabolizer (RM).
A higher value for change in PRU indicates a greater level of platelet inhibition.</description>
          <population>Pharmacodynamic analysis set is subset of FAS (≥1 genetics sample, ≥1 dose of study drug, ≥1 post-baseline PRU measurement, no significant protocol violations). Genetics subset LD population never used glycoprotein (GP) IIb/IIIa inhibitor during index hospitalization.
Participants classified as EM or RM. Invalid measurements of PRU were excluded.</population>
          <units>Change in PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 hours, EM (n=15, n=18, n=27, n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-162.9" spread="154.30" lower_limit="-397" upper_limit="144"/>
                    <measurement group_id="O2" value="-198.8" spread="90.71" lower_limit="-230" upper_limit="215"/>
                    <measurement group_id="O3" value="-217.2" spread="83.52"/>
                    <measurement group_id="O4" value="-9.7" spread="72.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours, RM (n=18, n=21, n=45, n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-245.9" spread="102.77"/>
                    <measurement group_id="O2" value="-183.3" spread="123.29"/>
                    <measurement group_id="O3" value="-181.9" spread="129.47"/>
                    <measurement group_id="O4" value="-22.2" spread="72.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days, EM (n=17, n=21, n=31, n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-193.9" spread="98.17"/>
                    <measurement group_id="O2" value="-196.5" spread="88.90"/>
                    <measurement group_id="O3" value="-187.5" spread="94.79"/>
                    <measurement group_id="O4" value="-110.6" spread="83.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days, RM (n=19, n=21. n=43, n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-250.3" spread="90.17"/>
                    <measurement group_id="O2" value="-208.5" spread="74.23"/>
                    <measurement group_id="O3" value="-152.8" spread="88.97"/>
                    <measurement group_id="O4" value="-81.7" spread="70.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 days, EM (n=12, n=18, n=30, n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-203.8" spread="102.89"/>
                    <measurement group_id="O2" value="-210.0" spread="110.68"/>
                    <measurement group_id="O3" value="-187.2" spread="92.70"/>
                    <measurement group_id="O4" value="-141.0" spread="75.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 days, RM (n=17, n=21, n=36, n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-267.5" spread="70.86"/>
                    <measurement group_id="O2" value="-225.7" spread="76.52"/>
                    <measurement group_id="O3" value="-164.1" spread="75.90"/>
                    <measurement group_id="O4" value="-100.7" spread="92.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of CV Death, Nonfatal MI, Nonfatal Stroke, UTVR, or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</title>
        <description>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Urgent Target Vessel Revascularization (UTVR), or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</description>
        <time_frame>30 days and 90 days</time_frame>
        <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60/10 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 60-mg LD followed by prasugrel 10-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30/7.5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 7.5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30/5 Primary</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel 300/75 Primary</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the primary cohort (participant weight ≥60 kg and age &lt;75 years)</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel 30/5 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive prasugrel 30-mg LD followed by prasugrel 5-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
          <group group_id="O6">
            <title>Clopidogrel 300/75 Low Weight/Elderly</title>
            <description>Population includes participants randomly assigned to receive clopidogrel 300-mg LD followed by clopidogrel 75-mg MD daily in the low weight/elderly cohort (participant weight &lt;60 kg or age ≥75 years)</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of CV Death, Nonfatal MI, Nonfatal Stroke, UTVR, or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</title>
          <description>Risk of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Urgent Target Vessel Revascularization (UTVR), or Recurrent Myocardial Ischemia Requiring Hospitalization (Analyzed Individually)</description>
          <population>As a consequence of the overall low number of reported clinical events, composite endpoints were not analyzed; thus zero participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel 60/10 Primary</title>
          <description>Primary = participant weight ≥60 kg and age &lt;75 years. Loading dose 60 mg followed by maintenance dose 10 mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Prasugrel 30/7.5 Primary</title>
          <description>Primary = participant weight ≥60 kg and age &lt;75 years. Loading dose 30mg followed by maintenance dose 7.5 mg/day</description>
        </group>
        <group group_id="E3">
          <title>Prasugrel 30/5 Primary</title>
          <description>Primary = participant weight ≥60 kg and age &lt;75 years. Loading dose 30 mg followed by maintenance dose 5 mg/day.</description>
        </group>
        <group group_id="E4">
          <title>Clopidogrel 300/75 Primary</title>
          <description>Primary = participant weight ≥60 kg and age &lt;75 years. Loading dose 300 mg followed by maintenance dose 75 mg/day</description>
        </group>
        <group group_id="E5">
          <title>Prasugrel 30/5 Low Weight/Elderly</title>
          <description>Low Weight/Elderly = participant weight &lt;60 kg or age ≥75 years. Loading dose 30 mg followed by maintenance dose 5 mg/day.</description>
        </group>
        <group group_id="E6">
          <title>Clopidogrel 300/75 Low Weight/Elderly</title>
          <description>Low Weight/Elderly = participant weight &lt;60 kg or age ≥75 years. Loading dose 300 mg followed by maintenance dose 75 mg/day</description>
        </group>
        <group group_id="E7">
          <title>Clopidogrel 300/75 No Weight</title>
          <description>Participant didn't have weight recorded. Loading dose 300 mg followed by maintenance dose 75 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tongue carcinoma stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypocholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Metastases to stomach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bradypnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Enema administration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

